Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00195312 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Vaccine in Adults With HIV
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
NCT00195312 is a Phase 1 study that was terminated before completion, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 91 participants.
The verdict
NCT00195312, a Phase 1 study, was terminated before completion, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
Study Summary
The main purpose of this study is to learn whether the study vaccine and the adjuvants(drugs that are used to help immune response) have an acceptable safety profile in treating individuals with HIV. A second purpose for this study is to understand how your immune system responds to the study vaccine with the adjuvants. Understanding these differences could be useful in several ways. First, it might help identify people whose disease is likely to respond to the study vaccine with the study adjuvants. Second, the information might be useful in developing other treatments for people whose disease does not respond to the study vaccine with the adjuvants.
Interventions
- BIOLOGICAL HIV-1 gag DNA (formulated with bupivacaine)
- BIOLOGICAL IL-15 DNA (formulated with bupivacaine)
- BIOLOGICAL IL-12 DNA (formulated with bupivacaine)
- BIOLOGICAL Sodium chloride injection USP (0.9%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2005-08 |
| Est. Completion | 2007-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00195312
The ClinicalTrials.gov registry entry for NCT00195312 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which HIV-1 gag DNA (formulated with bupivacaine) is the first listed.
NCT00195312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00195312 about?
NCT00195312 is a clinical study titled "Study Evaluating Vaccine in Adults With HIV". The main purpose of this study is to learn whether the study vaccine and the adjuvants(drugs that are used to help immune response) have an acceptable safety profile in treating individuals with HIV. A second purpose for this study is to understand how your immune system responds to the study vacci...
What is the current status of trial NCT00195312?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2005-08. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00195312?
The interventions under investigation include: HIV-1 gag DNA (formulated with bupivacaine) (BIOLOGICAL), IL-15 DNA (formulated with bupivacaine) (BIOLOGICAL), IL-12 DNA (formulated with bupivacaine) (BIOLOGICAL), Sodium chloride injection USP (0.9%) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00195312?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.